Research programme: peptide conjugate therapeutics - Esperance

Drug Profile

Research programme: peptide conjugate therapeutics - Esperance

Alternative Names: EP 200; EP 300; EP-302

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Esperance Pharmaceuticals
  • Class Antineoplastics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 May 2017 Preclinical development is ongoing in Cancer in USA (Esperance pipeline, May 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
  • 20 Apr 2010 Pharmacodynamics data from preclinical studies in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top